WHOOP is exploring a way to estimate glucose from the wrist without piercing the skin. A US patent application published July 16, 2026, outlines an optical system that could bring glucose-related measurements to a future wearable.
The filing is not a product announcement. WHOOP has not confirmed a device, published clinical accuracy data, disclosed an FDA submission or provided a launch timeline. For health-program operators and technology buyers, the application signals a research direction rather than a deployable medical capability.
US patent application US 2026/0198807 A1 describes two optical channels that would direct selected wavelengths of light into tissue. One channel would target a wavelength affected by glucose, while a reference channel would help account for interference caused by tissue, movement or device placement.
Gadgets & Wearables highlighted the filing and noted that it also discusses motion sensors and specialized light emitters, including quantum dots. The filing does not show that WHOOP has built an accurate or commercially viable sensor.
FDA history raises a higher bar
WHOOP would join Apple, Samsung, Garmin and Oura in pursuing wearable glucose capabilities. None sells a mainstream wrist device authorized to measure or estimate blood glucose independently. Apple’s glucose-monitoring research shows how years of patent activity and technical development can still fall short of a commercial product.
The FDA’s glucose-wearable safety communication says the agency has not authorized, cleared or approved a smartwatch or smart ring for that purpose. Inaccurate readings could lead users to take incorrect doses of insulin or other glucose-lowering medications.
The warning does not apply to watches that display readings from an authorized continuous glucose monitor. Those systems receive data from a separate sensor that pierces the skin and measures glucose in interstitial fluid.
WHOOP has faced FDA scrutiny over another estimated health metric. In a July 14, 2025, warning letter, the agency said Blood Pressure Insights was marketed without required clearance or approval because its systolic and diastolic estimates were tied to diagnosing hypertension and hypotension.
The FDA closed the matter after WHOOP changed the feature and its labeling. A June 17, 2026, closeout letter said the agency did not intend to enforce medical-device requirements against Blood Pressure Insights as modified, but limited that decision to the updated feature.
The decision does not establish a pathway for glucose monitoring, which would require a separate regulatory assessment.
Accuracy remains the missing proof
Optical glucose estimation must account for motion, temperature, hydration, skin contact and tissue differences. WHOOP has not published evidence showing that its proposed system can control those variables in real-world use.
A peer-reviewed Communications Medicine study published Dec. 24, 2025, illustrates the remaining limitations. Researchers used dual-channel photoplethysmography and machine learning to estimate fasting glucose, but the method still required one finger-stick calibration each month.
Accuracy varied among participant groups. Mean absolute relative difference was 9.59% among people not taking antidiabetic drugs and 16.40% among those using antidiabetic drugs alongside other medications. Measurements were collected while participants were seated, leaving real-world performance unresolved.
Software may provide nearer-term value by combining authorized CGM readings with sleep, activity and heart-rate data. AI-assisted glucose analysis could identify patterns without presenting the watch as a replacement for the medical sensor.
The application points to a WHOOP research direction, not a capability in current products. Until WHOOP provides clinical validation and a clear regulatory pathway, health programs and technology buyers should not treat wrist-only glucose estimates as ready for clinical use or enterprise deployment.
Read more: The broader smartwatch blood sugar landscape explains which devices can display CGM data now and why independent wrist-based measurement remains out of reach.